Treatment of iodine-negative thyroglobulin-positive thyroid cancer: Differences in outcome in patients with macrometastases and patients with micrometastases

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 11, 2004, Pages 1500-1504

  Kabasakal, Levent ^a   Selçuk, Nalan Alan ^a   Shafipour, Hojjet ^a   Ozmen, Ozlem ^a   Onsel, Cetin ^a   Uslu, Ilhami ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Radioiodine therapy; Thyroglobulin; Thyroid cancer; Whole body scan

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; SAMPLE SIZE; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; WHOLE BODY AUTORADIOGRAPHY;

ADULT; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THYROGLOBULIN; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 9944252005     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1516-y     Document Type: Article

References (21)

1. Atay-Rosenthal S. Controversies of treatment of well-differentiated thyroid carcinoma and factors influencing prognosis. In: Freeman LM, ed. Nuclear medicine annual. Philadelphia: Williams and Wilkins; 1999:3003-3334.
2. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 89:1447-1463.
3. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998; 138:249-252.
4. Schulumberger M, Arcangioli O, Pierkarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 1988; 29:1790-1794.
5. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488-1492.
6. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic I-131 whole body scan: comparison of patients treated with high I-131 activities versus untreated patients. J Clin Endocrinol Metab 2001; 86:4092-4097.
7. Kabasakal L. Treatment of iodine negative, thyroglobulin positive, thyroid cancer patients: Do we miss the target when we shoot in the dark? Nucl Med Commun 2003; 24:739-741.
8. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002; 87:1521-1526.
9. Waxman A, Ramanna L, Chapman N, et al. The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation. J Nucl Med 1981; 22:861-865.
10. Sherman SI, Tielens ET, Sostre S, Wharam MD, Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:629-634.
11. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A. Thrapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28:1888-1891.
12. De Keizer B, Koppeschaar HPF, Zelissen PMJ, Lips CJM, Rijk PP, Dijk A, de Klerk JMH. Efficacy of high therapeutic doses of ioidine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 2001; 28:198-202.
13. Mezzafferri EL. Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 1995; 80:1485-1487.
14. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 2000; 30:107-114.
15. Schlumberger M, challeton C, de Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37:598-605.
16. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626-1631.
17. Sera N, Ashizawa K, Ando T, et al. Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (1-131) therapy. Thyroid 2000; 10:975-979.
18. Schaap J, Eustatia-Rutten CFA, Stokkel M, Links TP, Diamant M, van der Velde EA, Romijn JA, Smit JWA. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma? Clin Endocrinol 2002; 57:117-124.
19. Helal BO, Merlet P, Tourbet ME, et al. Clinical impact of 18-F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results after therapy. J Nucl Med 2001; 42:1464-1469.
20. Sonmezoglu K, Kabasakal L, Ozmen O, Turkmen C, Onsel C, Bozluolcay S. Complementary role of FDG PET and Tc-99m MIBI scintigraphy in patients with differentiated thyroid cancer. Eur J Nucl Med 2003; 30:S279.
21. Schlumberger M, Mancusi F, Baudin E, Pacini F. I-131 therapy for elevated thyroglobulin levels. Thyroid 1997; 7:273-276.